| 2023-11-10: Implementation of statistical innovation in a pharmaceutical company | link | |
| 2023-10-13: Futility analyses – they are a strategic tool in drug development and not at all futile! | link | |
| 2023-10-12: Crossover in oncology trials - presentation at FDA / Lungevity statistical forum | link | |
| 2023-08-09: Minimal detectable difference in a trial with time-to-event primary endpoint | link | code | |
| 2023-08-05: Discussion of JSM session “Recent advances in Bayesian power and probability of success”, providing punch lines of my talk on quantitative decision-making | link | |
| 2023-07-12: Statistical Methodology Leaders in Drug Development | link | |
| 2023-07-06: Summary of talk at BBS next generation event | link | |
| 2023-07-05: Effective statistician podcast on driving statistical innovation | link | |
| 2023-06-06: Why can’t we simply get rid of RCTs? | link | |
| 2023-06-05: Why do we randomize in RCTs? | link | |
| 2023-04-02: Why do we do interim analyses in clinical trials? | link | |
| 2023-03-29: Quantification of follow-up | link | |
| 2023-03-07: How can the estimands addendum framework be “married” with competing risks? | link | |
| 2023-02-02: Trial design using multistate modelling for PFS and OS | link | |
| 2023-01-04: Estimation of AE risk in RCTs | link | |
| 2022-12-02: Are regulators on board with estimands? | link | |
| 2022-05-01: Thoughts on my 10th year anniversary at Roche | link | |
| 2022-02-09: Academia - Industry collaboration award of Ulm University for Roche’s long-term collaboration with Jan Beyersmann | link | |